Reply
Zoe Hall, Fiona Oakley, Michele Vacca, Julian L. Griffin – 25 January 2022
Will inhibition of cellular crosstalk resolve liver fibrosis?
Edward N. Harris – 25 January 2022
Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome
Marine Baptissart, Christine M. Bradish, Brie S. Jones, Evan Walsh, Jesse Tehrani, Vicmarie Marrero‐Colon, Sanya Mehta, Dereje D. Jima, Seh Hoon Oh, Anna Mae Diehl, Tiffany Fougeray, Hervé Guillou, Michael Cowley – 25 January 2022
LiverLearning®: Addiction Medicine for Liver Care Providers
DESCRIPTION There is growing interest among hepatology providers in incorporating addiction medicine skills in the evaluation of patients with addiction-related liver diseases, particularly alcohol-associated liver disease. Recent studies have shown an association between receipt of addiction treatment and improvements in liver-related outcomes in patients with alcohol-associated liver disease.
Reply
James M. Paik, Linda Henry, Zobair M. Younossi – 24 January 2022
Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification
Gianni Testino – 24 January 2022
Genomic medicine for liver disease
Melanie Zheng, Garrett Allington, Sílvia Vilarinho – 24 January 2022
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Haichuan Wang, Yi Zhou, Hongwei Xu, Xue Wang, Yi Zhang, Runze Shang, Marie O'Farrell, Stephanie Roessler, Carsten Sticht, Andreas Stahl, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen – 24 January 2022
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
Raluca Pais, Judith Aron‐Wisnewsky, Pierre Bedossa, Maharajah Ponnaiah, Jean‐Michel Oppert, Jean‐Michel Siksik, Laurent Genser, Frederic Charlotte, Dominique Thabut, Karine Clement, Vlad Ratziu – 24 January 2022
Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community‐Based Sample of Mexican‐Origin Adults
David O. Garcia, Kristin E. Morrill, Melissa Lopez‐Pentecost, Edgar A. Villavicencio, Rosa M. Vogel, Melanie L. Bell, Yann C. Klimentidis, David G. Marrero, Cynthia A. Thomson – 24 January 2022 – The incidence of nonalcoholic fatty liver disease (NAFLD) is highest among Mexican‐origin (MO) adults. Few studies have estimated the prevalence of NAFLD in this subpopulation, particularly by sex and age. We assessed the prevalence of NAFLD in a community sample of MO adults residing in a border region of southern Arizona and determined risk factors associated with NAFLD.